- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05293080
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE (EAST-STROKE)
December 27, 2023 updated by: Universitätsklinikum Hamburg-Eppendorf
This study will determine whether early, comprehensive, rhythm control therapy prevents adverse cardiovascular outcome in patients with acute ischemic stroke and atrial fibrillation compared to usual care.
Study Overview
Status
Not yet recruiting
Conditions
Detailed Description
trial fibrillation is the single most frequent cause of ischemic stroke and associated with a high risk of recurrent stroke and cardiovascular complications.
Usual care comprises oral anticoagulation and rate control.
However, it is unclear, whether early rhythm control therapy reduces the risk of recurrent stroke and cardiovascular outcomes in stroke patients with atrial fibrillation.
The Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE (EAST-STROKE) will be an investigator-initiated, prospective, randomized, open, blinded outcome assessment (PROBE) interventional multi-center trial to test whether early, comprehensive, rhythm control therapy prevents adverse cardiovascular outcome in patients with acute ischemic stroke and atrial fibrillation compared to usual care.
Primary outcome is a composite of recurrent stroke, cardiovascular death, and hospitalization due to worsening of heart failure or acute coronary syndrome.
Secondary outcomes will involve a comprehensive array of clinical and safety parameters, health and socio-economic outcomes including patient reported outcome measures.
In an adaptive design, up to 1,746 patients will be enrolled to demonstrate the expected treatment effect with 90% power.
Study Type
Interventional
Enrollment (Estimated)
1746
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Märit Jensen, MD
- Phone Number: +4940741053770
- Email: m.jensen@uke.de
Study Contact Backup
- Name: Götz Thomalla, MD
- Phone Number: +4940741050137
- Email: thomalla@uke.de
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Acute ischemic stroke in the previous four weeks, diagnosed by imaging (CT or MRI) or clinical diagnosis
- Possibility to start the trial treatment within 4 weeks after stroke, and as soon as clinically justifiable
- AF first detected ≤1 year prior to randomization
- Informed consent
Exclusion Criteria:
- End-stage cancer or life-expectancy < 12 months due to other advanced co-morbid illness
- Prior AF ablation or surgical therapy of AF
- Patients not suitable for rhythm control of AF due to cardiac conditions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Early rhythm control therapy
Patients with acute ischemic stroke and AF will receive either catheter ablation (mainly pulmonary vein isolation), or adequate antiarrhythmic drug therapy at an early time point.
The initial therapy will be selected by the local investigator.
In case of continuation or recurrence of AF, both modalities may be combined.
|
Therapy for early rhythm control will be either by use of approved antiarrhythmic drugs (e.g.
amiodarone, dronedarone, flecainide, propafenone), approved approaches and devices for ablation, or electric cardio version.
|
Active Comparator: Usual care
Patients with acute ischemic stroke and AF will receive usual care following the current ESC guidelines for AF treatment.
|
Usual care for atrial fibrillation according to current guidelines.
Usual care will mainly comprise rate control by approved drugs.
We expect, that usual care will also comprise therapy for rhythm control in a small group of patients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to first recurrent stroke, cardiovascular death, or hospitalization due to worsening of heart failure or due to acute coronary syndrome.
Time Frame: Through study completion, an average of 42 months
|
The primary outcome measure is a composite of first recurrent stroke, cardiovascular death, and hospitalization due to worsening of heart failure or due to acute coronary syndrome as recorded by study investigators
|
Through study completion, an average of 42 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to first recurrent stroke
Time Frame: Through study completion, an average of 42 months
|
Recurrent stroke as recorded by study investigators
|
Through study completion, an average of 42 months
|
Time to cardiovascular death
Time Frame: Through study completion, an average of 42 months
|
Through study completion, an average of 42 months
|
|
Time to first hospitalization due to worsening of heart failure
Time Frame: Through study completion, an average of 42 months
|
Hospitalization due to worsening of heart failure as recorded by study investigators
|
Through study completion, an average of 42 months
|
Time to hospitalization due to acute coronary syndrome
Time Frame: Through study completion, an average of 42 months
|
Hospitalization due to acute coronary syndrome as recorded by study investigators
|
Through study completion, an average of 42 months
|
Time to recurrent AF
Time Frame: Through study completion, an average of 42 months
|
Through study completion, an average of 42 months
|
|
Cardiovascular hospitalization
Time Frame: Through study completion, an average of 42 months
|
Cardiovascular hospitalization as recorded by study investigators
|
Through study completion, an average of 42 months
|
All-cause hospitalizations
Time Frame: Through study completion, an average of 42 months
|
All-cause hospitalizations as recorded by study investigators
|
Through study completion, an average of 42 months
|
Time in sinus rhythm
Time Frame: Through study completion, an average of 42 months
|
Through study completion, an average of 42 months
|
|
Functional status assessed by the modified Rankin Scale
Time Frame: at 12 and 24 months
|
Modified Ranking Scale ranging from 0 (no symptoms) to 6 (death) with lower values indicating better status
|
at 12 and 24 months
|
Quality of life assessed by the EuroQol five-dimensional questionnaire (EQ-5D)
Time Frame: at 12 and 24 months
|
The EQ-5D index will be calculated with higher values indicating better health state
|
at 12 and 24 months
|
Cognitive function assessed by the Montreal Cognitive Assessment (MoCA)
Time Frame: at 12 and 24 months
|
The MoCA ranges for 0 to 30, with higher values indicating better cognitive function
|
at 12 and 24 months
|
Cost of therapy
Time Frame: Through study completion, an average of 42 months
|
Through study completion, an average of 42 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: Through study completion, an average of 42 months
|
Death from any cause
|
Through study completion, an average of 42 months
|
Severe bleeding complications
Time Frame: Through study completion, an average of 42 months
|
Intracranial hemorrhage, major bleeding
|
Through study completion, an average of 42 months
|
Adverse events
Time Frame: Through study completion, an average of 42 months
|
Adverse events related to the study intervention with special emphasis on proarrhythmia and complications due to interventions
|
Through study completion, an average of 42 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Götz Thomalla, MD, Universitatsklinikum Hamburg-Eppendorf
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2024
Primary Completion (Estimated)
September 1, 2028
Study Completion (Estimated)
March 1, 2029
Study Registration Dates
First Submitted
March 1, 2022
First Submitted That Met QC Criteria
March 14, 2022
First Posted (Actual)
March 24, 2022
Study Record Updates
Last Update Posted (Actual)
December 28, 2023
Last Update Submitted That Met QC Criteria
December 27, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EAST-STROKE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)
-
Electrophysiology Research FoundationRecruitingHeart Failure | Atrial Fibrillation | Diastolic Heart FailureUnited States, Germany, Switzerland